Designing Vena Cava Filters with Textile Structures

2010 ◽  
pp. 334-341
Author(s):  
J. Yoon ◽  
M.W. King ◽  
E. Johnson
Keyword(s):  
2016 ◽  
Vol 10 (1) ◽  
pp. 30 ◽  
Author(s):  
Sonika Malik ◽  
◽  
Anju Bhardwaj ◽  
Matthew Eisen ◽  
Sanjay Gandhi ◽  
...  

Pulmonary embolism (PE) is an important cause of morbidity and mortality and presents with significant diagnostic and therapeutic challenges. Clinical presentation ranges from mild, nonspecific symptoms to syncope, shock, and sudden death. Patients with hemodynamic instability and/ or signs of right ventricular dysfunction are at high risk for adverse outcomes and may benefit from aggressive therapy and support. Therapeutic anticoagulation is indicated in all patients in the absence of contraindications. Thrombolysis should be strongly considered in selected high- and intermediate-risk patients, either by systemic infusion or percutaneous catheter-directed therapy. Other therapeutic modalities, such as vena cava filters and surgical embolectomy, are options for patients who fail or cannot tolerate anticoagulation and/or thrombolysis. This article reviews the assessment and advanced management options for acute PE with focus on high- and intermediate-risk patients.


2020 ◽  
Vol 43 (5) ◽  
pp. 800-802
Author(s):  
Meghana Halkar ◽  
Robert Ward ◽  
Erica Knavel Koepsel ◽  
Haraldur Bjarnason ◽  
Robert McBane ◽  
...  
Keyword(s):  

2019 ◽  
Vol 213 (4) ◽  
pp. 768-777 ◽  
Author(s):  
Ronald S. Winokur ◽  
Noy Bassik ◽  
David C. Madoff ◽  
David Trost

TH Open ◽  
2021 ◽  
Vol 05 (01) ◽  
pp. e73-e80
Author(s):  
Filip Ionescu ◽  
Nwabundo Anusim ◽  
Eva Ma ◽  
Lihua Qu ◽  
LeAnn M. Blankenship ◽  
...  

AbstractRecognition of the adverse events of inferior vena cava filters (VCFs) has prompted the Food and Drug Administration (FDA) to issue safety warnings (2010 and 2014), advocating for removal, once the risk of pulmonary embolism has abated. Despite an initial increase in retrieval rates, these remain low (25–30% at 1 year in 2014). We retrospectively investigated retrieval trends in adults with VCFs placed between 2015 and 2018 at a single institution. The rate of retrievable VCF removal accounting for the competing risk of death was the main outcome. There were 494 VCFs placed (305 retrievable). The cumulative incidence of retrieval remained low (21% at 1 year), even after the second FDA warning (2014). Patients who resumed anticoagulation (AC) at any time were more likely to have retrieval (hazard ratio [HR] = 3.6, p < 0.01) and had higher retrieval rates at every time point (31.4 vs. 7.6% at 1 year). Advanced age (HR = 0.98 per year, p = 0.004), stroke (HR = 0.28, p = 0.028), and active malignancy (HR = 0.42, p = 0.006) predicted nonretrieval. Device-related complications were infrequent (<1%) but thrombotic complications occurred early and were more common for nonretrieved VCFs (17 vs. 12%, p = 0.29). Revision of guidelines to recommend active surveillance for the ability to tolerate AC in the immediate postimplantation period may improve retrieval rates.


Author(s):  
Anil Pillai ◽  
Manoj Kathuria ◽  
Maria del Pilar Bayona Molano ◽  
Patrick Sutphin ◽  
Sanjeeva P Kalva

Sign in / Sign up

Export Citation Format

Share Document